Gainers
- Unity Biotechnology UBX shares increased by 95.3% to $1.66 during Friday's pre-market session. The market value of their outstanding shares is at $114.8 million.
- Rani Therapeutics Hldgs RANI stock moved upwards by 23.08% to $10.13. The company's market cap stands at $248.1 million. As per the press release, Q2 earnings came out 2 days ago.
- Larimar Therapeutics LRMR stock rose 18.68% to $2.35. The company's market cap stands at $41.6 million. The company's, Q2 earnings came out yesterday.
- LogicMark LGMK stock increased by 13.44% to $1.35. The company's market cap stands at $12.9 million. The company's, Q2 earnings came out yesterday.
- Neoleukin Therapeutics NLTX shares increased by 12.74% to $1.15. The company's market cap stands at $48.9 million. As per the press release, Q2 earnings came out 3 days ago.
- AirSculpt Technologies AIRS shares moved upwards by 12.61% to $10.0. The company's market cap stands at $556.4 million. As per the news, the Q2 earnings report came out today.
Losers
- Aptinyx APTX shares fell 36.5% to $0.38 during Friday's pre-market session. The company's market cap stands at $25.8 million.
- Co-Diagnostics CODX stock decreased by 30.79% to $4.47. The market value of their outstanding shares is at $151.0 million. The company's, Q2 earnings came out yesterday.
- PLx Pharma PLXP stock fell 16.61% to $2.16. The company's market cap stands at $59.4 million. As per the news, the Q2 earnings report came out today.
- Illumina ILMN shares decreased by 15.52% to $192.15. The market value of their outstanding shares is at $30.1 billion. As per the press release, Q2 earnings came out yesterday.
- Certara CERT shares fell 14.62% to $17.24. The company's market cap stands at $2.7 billion. The company's, Q2 earnings came out 3 days ago.
- AcelRx Pharmaceuticals ACRX shares declined by 12.9% to $0.27. The company's market cap stands at $40.0 million. As per the news, the Q2 earnings report came out yesterday. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Market News and Data brought to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in